Effective Treatment of Head and Neck Squamous Cell Carcinoma by An Oncolytic Herpes Simplex Virus

Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

“…A growing body of preclinical and clinical data suggests that oncolytic viral therapy could be an effective therapeutic modality in the treatment of advanced cancer. [5][6][7][8][9][10][11] Various strains of viruses, such as adenovirus, 12 herpes simplex virus, 13 Newcastle disease virus, measles virus, vesicular stomatitis virus and vaccinia virus 14 are being analyzed for their oncolytic capacity; some of these viruses have progressed to the clinical trial phase. Herpes simplex virus type 1 (HSV 1) is an ideal candidate for oncolytic viral therapy because of the following reasons: (a) it infects a broad range of hosts; (b) it causes lyses of the host cell at the end of viral replication; (c) it has a very large genome and therefore harbors many non-essential genes, mostly related to neuroinvasiveness that are expendable and can be replaced during the recombinant engineering process; (d) it can be controlled by antiviral drugs in the event of uncontrolled replication; and (e) its genome remains as an episome and does not incorporate in to the host genome, avoiding the risk of introducing mutations.…”

Virally-directed fluorescent imaging (VFI) can facilitate endoscopic staging

“…For example, at an MOI of 1, nearly 50% of the cells express GFP 1 day after infection, while 50% of those infected at MOI of 0.1 express GFP 3 to 4 days after infection (p < .001 vs. untreated control cells, t-test). Time course of in vivo GFP expression: Several previous studies from our laboratory have demonstrated the ability of NV1066 to replicate in in vivo in murine flank tumors (15). Viral titers increase over time as measured by real-time PCR for viral genomic DNA, with a large replication burst evident between 24 to 48 hours.…”

“…A number of studies from our group and others have determined that these viruses are highly specific for tumor cells while sparing normal cells (13)(14)(15)(16)(17)(18)(19)(20)(21). Oncolytic HSV therapy has shown to be effective against multiple tumor types including lung, esophageal, gastric, colorectal, gallbladder, hepatic, pancreatic, bladder cancer and mesothelioma (13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Given the specificity of herpes viral replication for tumor cells, we sought to determine whether NV1066, a HSV-1 mutant virus used in this study can delineate tumor tissue from normal tissue.…”

Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12

“…In animal models, these vectors have shown efficacy in treating a wide variety of malignancies including brain, breast, colorectal, prostate, and head and neck cancers (3)(4)(5)(6)(7). We have constructed a series of replicationcompetent, attenuated herpes oncolytic viruses sharing a common viral structure.…”